Developer docs
API playgroundTry for free, no card

Search company profiles

Calico Life Sciences

Full company profile

uuid0005ib9

Namestring
Calico Life Sciences
Legal namestring
Calico Life Sciences LLC
Websiteurl
calicolabs.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Calico Life Sciences is a privately held biotechnology research and development company founded by Alphabet Inc. in 2013 and headquartered in South San Francisco, California. The company focuses on understanding the biology of aging and translating those insights into therapeutics for age-related diseases, including neurodegeneration, cancer, and rare conditions such as Vanishing White Matter (VWM) disease and Autosomal Dominant Polycystic Kidney Disease (ADPKD). As a wholly-owned subsidiary of Alphabet, Calico operates with long-term parent funding rather than the typical short-cycle biotech financing model, and currently maintains five clinical-stage drug candidates alongside more than twenty early-stage programs.

Calico's pipeline is anchored by three clinical assets: fosigotifator (ABBV-CLS-7262), an eIF2B activator in Phase 1b/2 development for VWM disease that received FDA Breakthrough Therapy Designation in June 2026; ABBV-CLS-628, an anti-PAPP-A monoclonal antibody in Phase 2 for ADPKD that received FDA Fast Track Designation in October 2025 and Orphan Drug Designation in November 2025; and ABBV-CLS-484 (osunprotafib), a first-in-class PTPN2/N1 phosphatase inhibitor in Phase 1 for advanced solid tumors. The company has built proprietary research platforms that include machine learning and AI-driven drug discovery, the PERISCOPE genome-wide morphological profiling platform (analyzing more than 20,000 genes across 30 million cells), the Nellie automated organelle analysis tool (over 900 GitHub downloads), custom light-sheet microscopes, and the Miniature-chemostat Aging Device (MAD) for purifying aged yeast cells. Calico also partners with UK Biobank to analyze genetic, phenotypic, clinical, and lifestyle data from over 500,000 participants, supplemented by a £30 million repeat-imaging initiative across 60,000 participants.

Calico's business model is partnership-driven rather than commercial. The company relies on long-duration capital from Alphabet Inc. and on pharmaceutical partnerships for late-stage clinical development and commercialization. Its 11-year collaboration with AbbVie (2014-2025), which deployed approximately $1.75 billion in total investments and produced all five clinical-stage assets, was terminated in November 2025 following the failure of a research asset in an ALS trial, triggering approximately 100 layoffs. Calico has additionally executed out-licensing transactions, including a deal with Mabwell (Shanghai) Bioscience valued at over $600 million, and continues to operate investigator-led research labs supported by more than 200 peer-reviewed publications in journals including Nature and Nature Methods. Following the AbbVie exit, the company restructured its discovery leadership—appointing former AbbVie Vice President Philip Kym as Head of Drug Discovery in October 2025—and is positioning its assets for new development and commercialization partnerships.

Short descriptiontext

Alphabet-founded biotech Calico Life Sciences develops therapies for age-related diseases using integrated biology, computational methods, and drug discovery. It has five clinical-stage assets including fosigotifator (FDA Breakthrough Therapy Designation) and ABBV-CLS-628, supported by proprietary platforms and UK Biobank partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
aging biology research, age-related therapeutics, drug discovery biotechnology, longevity pharmaceutical research, computational biology platform
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Alphabet Funding
TypeLicensing Royalties
Description

Calico is funded by Alphabet Inc., which provides long-term capital for research and development operations. This is the primary funding source enabling the company's longevity research mission.

calicolabs.com
2AbbVie Collaboration Revenue
TypeLicensing Royalties
Description

Collaboration with AbbVie involves up to $1.5 billion in co-investment ($250M each initially with potential for additional $500M each). Parties share costs and profits equally. AbbVie supports clinical development and commercialization in exchange for rights to co-develop therapies.

3Licensing Partnerships
TypeLicensing Royalties
Description

Calico has secured licensing partnerships worth over $600 million with Mabwell for therapeutic programs, demonstrating ability to monetize technology through out-licensing.

theglobeandmail.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Calico Life Sciences is a research and development biotechnology company that discovers and develops therapeutics targeting the biology of aging and age-related diseases. It integrates basic research, computational biology, machine learning, and drug development to advance a pipeline of clinical-stage drug candidates (fosigotifator, ABBV-CLS-628, ABBV-CLS-484/osunprotafib) and more than 20 early-stage programs. Calico generates revenue primarily through licensing, partnerships, and funding from parent Alphabet Inc.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Fosigotifator blunted persistent ISR in brain and spinal cord in mouse VWM model, correcting coordination and movement problems
+3 more records
Product overview1 text field

Calico Life Sciences is an Alphabet-founded biotechnology company focused on understanding the biology of aging and developing interventions for age-related diseases. The company's therapeutic pipeline includes three clinical-stage drug candidates: fosigotifator (eIF2B activator for Vanishing White Matter disease with FDA Breakthrough Therapy Designation), ABBV-CLS-628 (anti-PAPP-A antibody for ADPKD with FDA Fast Track and Orphan Drug Designations), and ABBV-CLS-484/osunprotafib (PTPN2/N1 inhibitor for solid tumors). Calico operates five assets in clinical development with over 20 early-stage programs. The company integrates basic research with advanced computational biology and machine learning, maintaining proprietary research tools including Nellie (automated organelle analysis), PERISCOPE (genome-wide functional profiling), and custom microscopy technologies.

Product and service7 records
1Fosigotifator (ABBV-CLS-7262)
CategoryDrug Candidate
Description

Investigational eIF2B activator being developed as a potential treatment for Vanishing White Matter disease, an ultra-rare and progressive brain disorder. Currently in Phase 1b/2 clinical trial across adult, pediatric, and infant subjects. Granted FDA Breakthrough Therapy Designation and selected for FDA START Pilot Program.

2ABBV-CLS-628
CategoryDrug Candidate
Description

Investigational anti-PAPP-A monoclonal antibody designed to inhibit PAPP-A activity for treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Currently in Phase 2 clinical trials and granted FDA Fast Track and Orphan Drug Designations.

3ABBV-CLS-484 (Osunprotafib)
CategoryDrug Candidate
Description

First-in-class PTPN2/N1 phosphatase inhibitor designed to bolster anti-tumor responses by simultaneously targeting immune and tumor cells. In Phase 1 clinical trial for advanced solid tumors. Originally identified through the Broad Institute's TIDE platform.

4Nellie
CategoryResearch Tool / Software
Description

Automated organelle segmentation, tracking, and hierarchical feature extraction tool for 2D and 3D live-cell microscopy images. Published in Nature Methods and freely available on GitHub, downloaded over 900 times.

5PERISCOPE
CategoryResearch Platform / Software
Description

Image-based profiling platform combining Cell Painting, optical pooled CRISPR screening, and a scalable analysis pipeline for genome-wide functional characterization of gene perturbations. Analyzes over 20,000 genes in more than 30 million cells. Published in Nature Methods and publicly available on GitHub.

6High Numerical Aperture Single-Object Light-Sheet Microscope
CategoryResearch Instrument
Description

Custom microscope developed for high-resolution, fast, and gentle 3D imaging of living organisms. Plans and designs published on GitHub for open community access.

7Miniature-Chemostat Aging Device (MAD) Platform
CategoryResearch Platform / Technology
Description

Proprietary platform enabling scientists to purify 50 million old yeast cells in a single test tube, enabling genome-wide characterization of the molecular phenotypes of aging at scale.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-21
Description

Large-scale biomedical database partnership to study genetic and lifestyle information from over 500,000 participants. Calico collaborates with UK Biobank to analyze population-scale data combined with internal computing power and machine learning for insights into disease and aging mechanisms.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-09-03
Description

AbbVie and Calico announced a novel R&D collaboration to discover, develop and commercialize new therapies for age-related diseases. AbbVie and Calico each initially provided up to $250 million with potential for additional $500 million each. Calico responsible for research and early development through Phase 2a; AbbVie provides clinical development support and commercialization expertise. Costs and profits shared equally. Collaboration advanced five assets into clinical development before ending in November 2025 after an 11-year run, with approximately $1.75 billion total investment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Long-standing partnership established in 2014 and extended in 2019 and 2024. Collaboration focuses on understanding and treating diseases associated with aging, particularly cancer immunotherapy and neurodegeneration. Key achievements include development of PTPN2/N1 phosphatase inhibitor (ABBV-CLS-484) through the Tumor Immunotherapy Discovery Engine (TIDE) platform and collaborative work on Parkinson's disease targets.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Multiyear collaboration among Calico labs, University of Utah, and AbbVie to study the integrated stress response pathway and eIF2B. Research revealed that binding of sugar phosphates to eIF2B can activate it, suggesting a novel link between nutrient status and protein synthesis.

5Brad Pentelute Lab at MIT
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on HPV therapeutics using expertise in developing methods to modulate protein properties and functions to create new tools that block HPV's cancer-causing interactions. Partnership extended scope of Calico's peptide-based therapeutics research.

calicolabs.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration to discover genetic variants linked to liver fat accumulation and assess their impact on health risks using UK Biobank data.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration with University of Lincoln to study liver fat accumulation and health risks using UK Biobank data combined with Calico's bioinformatics capabilities.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Calico licensed Integrated Stress Response (ISR) modulators from UCSF, a foundational step for future clinical programs including eIF2B activator fosigotifator.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AbbVie was Calico's 11-year R&D partner for age-related diseases (terminated Nov 2025) and is a major pharmaceutical incumbent developing therapies across multiple therapeutic areas. Comparable as both a former collaborator and a broader incumbent whose strategy shift away from small molecules aligns with Calico's pivot to injectables/genetic medicines.

TypeDirect peer
Description

Insilico Medicine is an AI-driven drug discovery company with a focus on aging and age-related diseases, combining generative AI with biological validation. Comparable to Calico in its AI/ML drug discovery approach and aging biology focus, though operating as a commercial-stage company.

TypeDirect peer
Description

Unity Biotechnology develops therapeutics to eliminate senescent cells and address age-related diseases. Directly comparable as an aging-biology-focused clinical-stage biotech, though publicly traded and smaller in scale than Calico.

TypeDirect peer
Description

Altos Labs is a well-capitalized biotech focused on cellular rejuvenation programming to treat age-related diseases, with backing from Jeff Bezos and Yuri Milner. It is directly comparable to Calico in mission scope (biology of aging), funding model (patient long-term capital), and lack of approved products.

TypeDirect peer
Description

Recursion combines high-throughput biology with machine learning for drug discovery across multiple therapeutic areas including aging-related diseases. Comparable to Calico in its AI/ML-driven approach to target discovery and use of large-scale image-based profiling.

6Turn Biotechnologies
TypeEmerging player
Description

Turn Biotechnologies develops mRNA-based therapies for cellular reprogramming to treat age-related conditions. Comparable to Calico's recent strategic pivot toward injectable therapies and genetic medicines for age-related diseases.

TypeDirect peer
Description

Life Biosciences is a longevity biotech developing therapeutics that target the biology of aging across multiple age-related conditions. Directly comparable mission (extending healthy human lifespan) with similar pre-clinical/early-clinical stage of development.

TypeEmerging player
Description

NewLimit is a startup founded by Brian Armstrong focused on epigenetic reprogramming therapies for aging. Comparable to Calico in aging-biology focus and well-capitalized private structure, though earlier-stage and more narrowly focused on cellular reprogramming.

TypeOthers
Description

Mabwell is a Chinese biopharmaceutical company that licensed Calico therapeutic programs in a deal worth over $600M. Comparable as a partner/licensee validating Calico's out-licensing model, though Mabwell itself operates in adjacent rather than overlapping therapeutic space.

TypeBroad incumbent
Description

Genentech is a major biotechnology incumbent whose former CEO (Art Levinson) founded Calico. Comparable as a broad R&D-driven biotech whose leadership talent and scientific approach have directly shaped Calico's organizational DNA.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Calico Life Sciences

Biopharmaceuticalscalicolabs.com

Alphabet-founded biotech Calico Life Sciences develops therapies for age-related diseases using integrated biology, computational methods, and drug discovery. It has five clinical-stage assets including fosigotifator (FDA Breakthrough Therapy Designation) and ABBV-CLS-628, supported by proprietary platforms and UK Biobank partnerships.

What Calico Life Sciences does

Calico Life Sciences is a privately held biotechnology research and development company founded by Alphabet Inc. in 2013 and headquartered in South San Francisco, California. The company focuses on understanding the biology of aging and translating those insights into therapeutics for age-related diseases, including neurodegeneration, cancer, and rare conditions such as Vanishing White Matter (VWM) disease and Autosomal Dominant Polycystic Kidney Disease (ADPKD). As a wholly-owned subsidiary of Alphabet, Calico operates with long-term parent funding rather than the typical short-cycle biotech financing model, and currently maintains five clinical-stage drug candidates alongside more than twenty early-stage programs.

Calico's pipeline is anchored by three clinical assets: fosigotifator (ABBV-CLS-7262), an eIF2B activator in Phase 1b/2 development for VWM disease that received FDA Breakthrough Therapy Designation in June 2026; ABBV-CLS-628, an anti-PAPP-A monoclonal antibody in Phase 2 for ADPKD that received FDA Fast Track Designation in October 2025 and Orphan Drug Designation in November 2025; and ABBV-CLS-484 (osunprotafib), a first-in-class PTPN2/N1 phosphatase inhibitor in Phase 1 for advanced solid tumors. The company has built proprietary research platforms that include machine learning and AI-driven drug discovery, the PERISCOPE genome-wide morphological profiling platform (analyzing more than 20,000 genes across 30 million cells), the Nellie automated organelle analysis tool (over 900 GitHub downloads), custom light-sheet microscopes, and the Miniature-chemostat Aging Device (MAD) for purifying aged yeast cells. Calico also partners with UK Biobank to analyze genetic, phenotypic, clinical, and lifestyle data from over 500,000 participants, supplemented by a £30 million repeat-imaging initiative across 60,000 participants.

Calico's business model is partnership-driven rather than commercial. The company relies on long-duration capital from Alphabet Inc. and on pharmaceutical partnerships for late-stage clinical development and commercialization. Its 11-year collaboration with AbbVie (2014-2025), which deployed approximately $1.75 billion in total investments and produced all five clinical-stage assets, was terminated in November 2025 following the failure of a research asset in an ALS trial, triggering approximately 100 layoffs. Calico has additionally executed out-licensing transactions, including a deal with Mabwell (Shanghai) Bioscience valued at over $600 million, and continues to operate investigator-led research labs supported by more than 200 peer-reviewed publications in journals including Nature and Nature Methods. Following the AbbVie exit, the company restructured its discovery leadership—appointing former AbbVie Vice President Philip Kym as Head of Drug Discovery in October 2025—and is positioning its assets for new development and commercialization partnerships.

Calico Life Sciences firmographics

Firmographics
Name
Calico Life Sciences
Legal name
Calico Life Sciences LLC
Website
https://calicolabs.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
251–500 employees
Short description
Alphabet-founded biotech Calico Life Sciences develops therapies for age-related diseases using integrated biology, computational methods, and drug discovery. It has five clinical-stage assets including fosigotifator (FDA Breakthrough Therapy Designation) and ABBV-CLS-628, supported by proprietary platforms and UK Biobank partnerships.
Ownership category
akta.pro rank

Where Calico Life Sciences is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Calico Life Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

  1. Alphabet Funding: Calico is funded by Alphabet Inc., which provides long-term capital for research and development operations. This is the primary funding source enabling the company's longevity research mission.
  2. AbbVie Collaboration Revenue: Collaboration with AbbVie involves up to $1.5 billion in co-investment ($250M each initially with potential for additional $500M each). Parties share costs and profits equally. AbbVie supports clinical development and commercialization in exchange for rights to co-develop therapies.
  3. Licensing Partnerships: Calico has secured licensing partnerships worth over $600 million with Mabwell for therapeutic programs, demonstrating ability to monetize technology through out-licensing.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Calico Life Sciences product offering

Product offering

Core offering

Calico Life Sciences is a research and development biotechnology company that discovers and develops therapeutics targeting the biology of aging and age-related diseases. It integrates basic research, computational biology, machine learning, and drug development to advance a pipeline of clinical-stage drug candidates (fosigotifator, ABBV-CLS-628, ABBV-CLS-484/osunprotafib) and more than 20 early-stage programs. Calico generates revenue primarily through licensing, partnerships, and funding from parent Alphabet Inc.

Product overview

Calico Life Sciences is an Alphabet-founded biotechnology company focused on understanding the biology of aging and developing interventions for age-related diseases. The company's therapeutic pipeline includes three clinical-stage drug candidates: fosigotifator (eIF2B activator for Vanishing White Matter disease with FDA Breakthrough Therapy Designation), ABBV-CLS-628 (anti-PAPP-A antibody for ADPKD with FDA Fast Track and Orphan Drug Designations), and ABBV-CLS-484/osunprotafib (PTPN2/N1 inhibitor for solid tumors). Calico operates five assets in clinical development with over 20 early-stage programs. The company integrates basic research with advanced computational biology and machine learning, maintaining proprietary research tools including Nellie (automated organelle analysis), PERISCOPE (genome-wide functional profiling), and custom microscopy technologies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Fosigotifator (ABBV-CLS-7262) Investigational eIF2B activator being developed as a potential treatment for Vanishing White Matter disease, an ultra-rare and progressive brain disorder. Currently in Phase 1b/2 clinical trial across adult, pediatric, and infant subjects. Granted FDA Breakthrough Therapy Designation and selected for FDA START Pilot Program.
  • ABBV-CLS-628 Investigational anti-PAPP-A monoclonal antibody designed to inhibit PAPP-A activity for treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Currently in Phase 2 clinical trials and granted FDA Fast Track and Orphan Drug Designations.
  • ABBV-CLS-484 (Osunprotafib) First-in-class PTPN2/N1 phosphatase inhibitor designed to bolster anti-tumor responses by simultaneously targeting immune and tumor cells. In Phase 1 clinical trial for advanced solid tumors. Originally identified through the Broad Institute's TIDE platform.
  • Nellie Automated organelle segmentation, tracking, and hierarchical feature extraction tool for 2D and 3D live-cell microscopy images. Published in Nature Methods and freely available on GitHub, downloaded over 900 times.
  • PERISCOPE Image-based profiling platform combining Cell Painting, optical pooled CRISPR screening, and a scalable analysis pipeline for genome-wide functional characterization of gene perturbations. Analyzes over 20,000 genes in more than 30 million cells. Published in Nature Methods and publicly available on GitHub.
  • High Numerical Aperture Single-Object Light-Sheet Microscope Custom microscope developed for high-resolution, fast, and gentle 3D imaging of living organisms. Plans and designs published on GitHub for open community access.
  • Miniature-Chemostat Aging Device (MAD) Platform Proprietary platform enabling scientists to purify 50 million old yeast cells in a single test tube, enabling genome-wide characterization of the molecular phenotypes of aging at scale.

Quantifiable outcome

  • Fosigotifator blunted persistent ISR in brain and spinal cord in mouse VWM model, correcting coordination and movement problems
  • +3 more outcomes

Companies that use Calico Life Sciences

Customer profile

Segments1 record

Ideal customer profiles2 records

Calico Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature10 records

Calico Life Sciences partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • UK BiobankcoreStrategic or Co-development Partner · 21 September 2022Large-scale biomedical database partnership to study genetic and lifestyle information from over 500,000 participants. Calico collaborates with UK Biobank to analyze population-scale data combined with internal computing power and machine learning for insights into disease and aging mechanisms.
  • AbbViecoreStrategic or Co-development Partner · 3 September 2014AbbVie and Calico announced a novel R&D collaboration to discover, develop and commercialize new therapies for age-related diseases. AbbVie and Calico each initially provided up to $250 million with potential for additional $500 million each. Calico responsible for research and early development through Phase 2a; AbbVie provides clinical development support and commercialization expertise. Costs and profits shared equally. Collaboration advanced five assets into clinical development before ending in November 2025 after an 11-year run, with approximately $1.75 billion total investment.
  • Broad Institute of MIT and HarvardcoreStrategic or Co-development Partner · 1 January 2014Long-standing partnership established in 2014 and extended in 2019 and 2024. Collaboration focuses on understanding and treating diseases associated with aging, particularly cancer immunotherapy and neurodegeneration. Key achievements include development of PTPN2/N1 phosphatase inhibitor (ABBV-CLS-484) through the Tumor Immunotherapy Discovery Engine (TIDE) platform and collaborative work on Parkinson's disease targets.
  • University of UtahminorStrategic or Co-development PartnerMultiyear collaboration among Calico labs, University of Utah, and AbbVie to study the integrated stress response pathway and eIF2B. Research revealed that binding of sugar phosphates to eIF2B can activate it, suggesting a novel link between nutrient status and protein synthesis.
  • Brad Pentelute Lab at MITminorStrategic or Co-development PartnerCollaboration on HPV therapeutics using expertise in developing methods to modulate protein properties and functions to create new tools that block HPV's cancer-causing interactions. Partnership extended scope of Calico's peptide-based therapeutics research.
  • University of WestminsterminorStrategic or Co-development PartnerResearch collaboration to discover genetic variants linked to liver fat accumulation and assess their impact on health risks using UK Biobank data.
  • University of LincolnminorStrategic or Co-development PartnerResearch collaboration with University of Lincoln to study liver fat accumulation and health risks using UK Biobank data combined with Calico's bioinformatics capabilities.
  • University of California, San Francisco (UCSF)minorStrategic or Co-development PartnerCalico licensed Integrated Stress Response (ISR) modulators from UCSF, a foundational step for future clinical programs including eIF2B activator fosigotifator.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Calico Life Sciences competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: AbbVie was Calico's 11-year R&D partner for age-related diseases (terminated Nov 2025) and is a major pharmaceutical incumbent developing therapies across multiple therapeutic areas. Comparable as both a former collaborator and a broader incumbent whose strategy shift away from small molecules aligns with Calico's pivot to injectables/genetic medicines.
  • Genentech: Genentech is a major biotechnology incumbent whose former CEO (Art Levinson) founded Calico. Comparable as a broad R&D-driven biotech whose leadership talent and scientific approach have directly shaped Calico's organizational DNA.

Direct peers

  • Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company with a focus on aging and age-related diseases, combining generative AI with biological validation. Comparable to Calico in its AI/ML drug discovery approach and aging biology focus, though operating as a commercial-stage company.
  • Unity Biotechnology: Unity Biotechnology develops therapeutics to eliminate senescent cells and address age-related diseases. Directly comparable as an aging-biology-focused clinical-stage biotech, though publicly traded and smaller in scale than Calico.
  • Altos Labs: Altos Labs is a well-capitalized biotech focused on cellular rejuvenation programming to treat age-related diseases, with backing from Jeff Bezos and Yuri Milner. It is directly comparable to Calico in mission scope (biology of aging), funding model (patient long-term capital), and lack of approved products.
  • Recursion Pharmaceuticals: Recursion combines high-throughput biology with machine learning for drug discovery across multiple therapeutic areas including aging-related diseases. Comparable to Calico in its AI/ML-driven approach to target discovery and use of large-scale image-based profiling.
  • Life Biosciences: Life Biosciences is a longevity biotech developing therapeutics that target the biology of aging across multiple age-related conditions. Directly comparable mission (extending healthy human lifespan) with similar pre-clinical/early-clinical stage of development.

Emerging players

  • Turn Biotechnologies: Turn Biotechnologies develops mRNA-based therapies for cellular reprogramming to treat age-related conditions. Comparable to Calico's recent strategic pivot toward injectable therapies and genetic medicines for age-related diseases.
  • NewLimit: NewLimit is a startup founded by Brian Armstrong focused on epigenetic reprogramming therapies for aging. Comparable to Calico in aging-biology focus and well-capitalized private structure, though earlier-stage and more narrowly focused on cellular reprogramming.

Others

  • Mabwell Bioscience: Mabwell is a Chinese biopharmaceutical company that licensed Calico therapeutic programs in a deal worth over $600M. Comparable as a partner/licensee validating Calico's out-licensing model, though Mabwell itself operates in adjacent rather than overlapping therapeutic space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Calico Life Sciences social profiles

Digital presence

Calico Life Sciences compliance and trust

Trust signal

Compliance4 records

Calico Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Calico Life Sciences leadership team

Management profile

Number of profiles

Profiles10 records

Calico Life Sciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Calico Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Calico Life Sciences

What does Calico Life Sciences do?

Calico Life Sciences is a research and development biotechnology company that discovers and develops therapeutics targeting the biology of aging and age-related diseases. It integrates basic research, computational biology, machine learning, and drug development to advance a pipeline of clinical-stage drug candidates (fosigotifator, ABBV-CLS-628, ABBV-CLS-484/osunprotafib) and more than 20 early-stage programs. Calico generates revenue primarily through licensing, partnerships, and funding from parent Alphabet Inc.

Is Calico Life Sciences a public or private company?

Calico Life Sciences is a private company. It is classified as corporate owned and is currently operating.

When was Calico Life Sciences founded?

Calico Life Sciences was founded in 2013. It employs 251 to 500 people.

Where is Calico Life Sciences based?

Calico Life Sciences is headquartered in South San Francisco, United States, in the North America region.

How does Calico Life Sciences make money?

Three revenue lines are on record. Alphabet Funding is the primary driver. The others are abbVie Collaboration Revenue and licensing Partnerships.

Who are Calico Life Sciences's main competitors?

Broad incumbents on record are AbbVie and Genentech. Direct peers are Insilico Medicine, Unity Biotechnology, Altos Labs, Recursion Pharmaceuticals and Life Biosciences. Emerging players are Turn Biotechnologies and NewLimit. Mabwell Bioscience is listed as an others.

Does Calico Life Sciences have an API?

No public API is recorded for Calico Life Sciences.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCalico Life Sciences Announces European Medicines Agency Grants PRIME Designation to Investigational Fosigotifator for Vanishing White MatterThe European Medicines Agency granted PRIME designation to Calico's investigational fosigotifator for vanishing white matter, based on early Phase 1b/2 data. The designation follows the FDA's Breakthrough Therapy designation and follows the EMA's PRIME scheme for unmet medical needs. No approved treatments exist for VWM.Longevity.TechnologyCalico targets longevity pathway with rare disease winCalico Life Sciences has received FDA Breakthrough Therapy Designation for fosigotifator, its investigational eIF2B activator for Vanishing White Matter disease, an ultra-rare inherited leukodystrophy with no approved treatments. The designation highlights a mechanism targeting the Integrated Stress Response pathway that has broader implications for age-related neurodegenerative diseases such as Alzheimer's and ALS. This represents one of the first attempts to translate ISRIB-based research from Peter Walter's laboratory into human clinical development, with the Alphabet-backed company using rare disease research as a pathway to validate longevity-relevant mechanisms.PR NewswireCalico Life Sciences Announces Fosigotifator Granted Breakthrough Therapy Designation by the U.S. FDA for the Treatment of Vanishing White Matter DiseaseCalico Life Sciences announced that the FDA granted Breakthrough Therapy Designation to fosigotifator, an investigational eIF2B activator, for the treatment of Vanishing White Matter disease, an ultra-rare and progressive brain disorder with no approved treatments or cure. The designation, based on preliminary clinical evidence, follows the drug's prior selection for the FDA's START program, which supports accelerating novel treatments for rare diseases. Fosigotifator is currently in a Phase 1b/2 clinical trial evaluating safety, tolerability, pharmacokinetics, and exploratory efficacy across adult, pediatric, and infant subjects.Google DeepMindCo-Scientist: A multi-agent AI partner to accelerate researchGoogle has published research on Co-Scientist, a multi-agent AI system built with Gemini that helps researchers generate, debate, and evolve scientific hypotheses, making it available to individual researchers through a new experimental tool. The system uses specialized agents organized in phases—generating ideas, debating through simulated peer review, and evolving top-ranked hypotheses—and has been tested with collaborators including Calico Life Sciences, Stanford University, and the University of Edinburgh, where it has produced validated scientific results such as novel hypotheses for aging and liver disease treatments. Google plans to expand access to more Google Cloud enterprise partners and academic institutions in the coming weeks.Google DeepMindCo-ScientistCalico Life Sciences utilized the Co-Scientist AI tool to analyze aging biology literature, resulting in a novel hypothesis regarding the integrated stress response and its regulation by metabolism. The company's research team used the system to refine experimental designs and validate findings that have significant implications for understanding health and disease. Calico plans to publish these results based on the insights generated by the AI-assisted workflow.The Globe and MailEmpowered by Pipeline and Forged by Technology: Mabwell Successfully Lists on the Main Board of HKEXMabwell (Shanghai) Bioscience Co., Ltd., a Chinese innovative pharmaceutical company specializing in oncology, immunology, ophthalmology, and orthopedics therapeutics, officially listed on the Main Board of the Hong Kong Stock Exchange on April 28, 2026. The company has 4 commercialized products and 10 drug candidates in development, including its core ADC product 9MW2821, and has secured international licensing partnerships worth up to US$412.5 million with Disc Medicine and over US$600 million with Calico Life Sciences. The listing is expected to accelerate development of its ADC pipeline and expand its global commercialization efforts across emerging markets.GenengnewsTerray’s AI Model Accelerates Drug Potency Prediction, Pose Not NeededTerray Therapeutics unveiled TerraBind, an AI model for small molecule potency prediction that demonstrates approximately 20% increased accuracy and 26 times more efficiency compared to the widely adopted Boltz-2 open-source model developed by MIT researchers. Unlike co-folding models such as AlphaFold, TerraBind's architecture bypasses computationally intensive molecular structure determination to predict drug potency directly, enabling broader chemical space screening. The company has collaborations with Bristol Myers Squibb, Calico Life Sciences, Gilead, and Odyssey; achieved its first BMS milestone in December; and projects its platform will double small molecule drug development speed, with its first candidate expected in the clinic by 2027.Simply Wall StABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A UncertaintyAnalysts have trimmed AbbVie price targets slightly, reflecting more conservative revenue growth assumptions while raising profit margin expectations, amid mixed views on competition and pipeline visibility for key immunology drugs. AbbVie publicly denied media reports that it was in advanced talks to acquire Revolution Medicines for approximately $20 billion, following a sharp move in Revolution Medicines shares on the initial reports; the company also announced it is ending its decade-long partnership with Alphabet-funded Calico Life Sciences, resulting in layoffs of chemists involved in joint drug discovery.PR NewswireCalico Appoints Joseph R. Arron, M.D., Ph.D., as Head of Human Biology and GeneticsCalico Life Sciences LLC, a clinical-stage biotechnology organization focused on aging and age-related diseases founded by Alphabet Inc. and Arthur D. Levinson, announced the appointment of Joseph R. Arron, M.D., Ph.D. as Head of Human Biology and Genetics. Dr. Arron joins from Sonoma Biotherapeutics where he served as Chief Scientific Officer and Head of R&D, and previously held senior roles at 23andMe Therapeutics and Genentech. In this role, Dr. Arron will lead Calico's efforts to use large-scale human cohorts to discover and validate novel therapeutic targets for age-related diseases.